Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bacterial Vaginosis
Bacterio-therapeutics company receives NIH grant for bacterial vaginosis
July 14th, 2005
Osel, Inc., announced award of a multiple-year grant from the NIAID, U.S. National Institutes of Health (NIH) towards development of an encapsulated MucoCept Lactobacillus strain for therapeutic prevention of bacterial vaginosis (BV) and HIV infection under support of the Partnerships for Topical Microbicides. The scale of the AIDS crisis now surpasses even the worst-case scenarios of a decade ago. Around the world, approximately 40 million people are living with HIV/AIDS. The predominant mode of HIV transmission worldwide is via heterosexual contact, and women appear to be at greatest risk for HIV infection. The need to develop a simple, cost-effective,...
Source: Women's Health Weekly (2005-07-14)
|
